424 related articles for article (PubMed ID: 26923912)
41. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
[TBL] [Abstract][Full Text] [Related]
42. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
43. Cutaneous T-cell lymphoma.
Gemmill R
Semin Oncol Nurs; 2006 May; 22(2):90-6. PubMed ID: 16720231
[TBL] [Abstract][Full Text] [Related]
44. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma.
Nguyen CV; Bohjanen KA
Dermatol Clin; 2015 Oct; 33(4):683-96. PubMed ID: 26433841
[TBL] [Abstract][Full Text] [Related]
45. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
46. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2017 Oct; 92(10):1085-1102. PubMed ID: 28872191
[TBL] [Abstract][Full Text] [Related]
47. [Cutaneous lymphomas].
Schad K; Baumann Conzett K; Cozzio A
Ther Umsch; 2010 Sep; 67(9):453-64. PubMed ID: 20806174
[TBL] [Abstract][Full Text] [Related]
48. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
Olsen EA; Rook AH; Zic J; Kim Y; Porcu P; Querfeld C; Wood G; Demierre MF; Pittelkow M; Wilson LD; Pinter-Brown L; Advani R; Parker S; Kim EJ; Junkins-Hopkins JM; Foss F; Cacchio P; Duvic M
J Am Acad Dermatol; 2011 Feb; 64(2):352-404. PubMed ID: 21145619
[TBL] [Abstract][Full Text] [Related]
49. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sézary Syndrome.
Alhusayen R; Vu TT; Almuhanna N; Wohlmuth-Wieser I; Hardin J; Hughes JM; Chia J; Street L; Shear NH; Walsh SR; Gniadecki R
Dermatology; 2021; 237(3):479-485. PubMed ID: 33429396
[TBL] [Abstract][Full Text] [Related]
51. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust MS; Rook AH; Porcu P; Foss F; Moskowitz AJ; Shustov A; Shanbhag S; Sokol L; Fling SP; Ramchurren N; Pierce R; Davis A; Shine R; Li S; Fong S; Kim J; Yang Y; Blumenschein WM; Yearley JH; Das B; Patidar R; Datta V; Cantu E; McCutcheon JN; Karlovich C; Williams PM; Subrahmanyam PB; Maecker HT; Horwitz SM; Sharon E; Kohrt HE; Cheever MA; Kim YH
J Clin Oncol; 2020 Jan; 38(1):20-28. PubMed ID: 31532724
[TBL] [Abstract][Full Text] [Related]
52. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
53. The treatment of mycosis fungoides.
Mestel DS; Beyer M; Steinhoff M; Sterry W; Assaf C
G Ital Dermatol Venereol; 2008 Dec; 143(6):395-408. PubMed ID: 19169212
[TBL] [Abstract][Full Text] [Related]
54. Mycosis fungoides and the Sézary syndrome.
Foss F
Curr Opin Oncol; 2004 Sep; 16(5):421-8. PubMed ID: 15314509
[TBL] [Abstract][Full Text] [Related]
55. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I; Reneau JC; Hanel W; Chung CG
Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
[TBL] [Abstract][Full Text] [Related]
56. Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or Sézary Syndrome.
Quaglino P; Fava P; Pileri A; Grandi V; Sanlorenzo M; Panasiti V; Guglielmo A; Alberti-Violetti S; Novelli M; Astrua C; Rubatto M; Tonella L; Berti E; Pimpinelli N; Osella Abate S; Fierro MT; Vermeer M; Scarisbrick JJ; Ribero S
J Invest Dermatol; 2021 Mar; 141(3):484-495. PubMed ID: 33162051
[TBL] [Abstract][Full Text] [Related]
57. Cutaneous T-cell lymphoma: a review.
Winkler CF; Bunn PA
Crit Rev Oncol Hematol; 1983; 1(1):49-92. PubMed ID: 6083835
[TBL] [Abstract][Full Text] [Related]
58. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
59. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
60. Myocosis fungoides--an update on a non-mycotic disease.
Makdisi J; Friedman A
J Drugs Dermatol; 2013 Jul; 12(7):825-31. PubMed ID: 23884501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
